ArticleJournal of the American College of Cardiology2022
Association of Lipoprotein(a) With Atherosclerotic Plaque Progression.
Article in Journal of the American College of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 3 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- Association of Lp(a) with coronary plaque burden and high-risk plaque features: A meta-analysis of imaging studies.Atherosclerosis · 2026Pooled it
- The Association of Lipoprotein(a) with Major Adverse Cardiovascular Events after Acute Myocardial Infarction: A Meta-Analysis of Cohort Studies.Reviews in cardiovascular medicine · 2025Pooled it
- The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta-analysis.BioMed research international · 2022Pooled it
- Association of Elevated Lipoprotein(a) levels with vulnerable plaque features assessed by multimodality coronary imaging in patients with coronary artery disease: A systematic review and Meta-analysis.International journal of cardiology. Heart & vasculature · 2026Review
- Observational study: Temporal dynamics of lipoprotein(a) after out-of-hospital cardiac arrest: The Biobank Working Group.Resuscitation plus · 2026Article
- Risk stacking in peripheral artery disease (PAD): Integrating genetics, cardiometabolic disease and social determinants of health to explain worsening PAD outcomes.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- The Evolving Role of Coronary Artery Imaging in Assessing Cardiovascular Risk from Lipoprotein(a).Current atherosclerosis reports · 2026Review
- Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study.Journal of the American College of Cardiology · 2026Article
- Predictive Value of Lipoprotein(a) Combined with the Suita Score for High-Risk Plaque in Japanese Patients.Journal of atherosclerosis and thrombosis · 2026Article
- Positive association of lipoprotein(a) and the prevalence of lower extremity arterial disease in MASLD: a cross-sectional study.BMC cardiovascular disorders · 2026Article
- A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques.NPJ cardiovascular health · 2026Review
- Article
- Lipoprotein(a) epidemiology and role in secondary and primary-and-a-half cardiovascular prevention: From subclinical atherosclerosis to coronary events.American journal of preventive cardiology · 2026Article
- Metabolic, inflammatory, and lipoprotein(a)-related risk profiling for incident ASCVD: a multi-biomarker study.Frontiers in endocrinology · 2026Article
- Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention.Methodist DeBakey cardiovascular journal · 2026Review
- Presumed Mechanisms Underlying Lipoprotein(a)-caused Atherosclerosis.European cardiology · 2026Review
- Lipoprotein(a) and plaque progression: insights from serial coronary computed tomography angiography and quantitative plaque assessment.Frontiers in cardiovascular medicine · 2026Article
- Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies.European journal of clinical investigation · 2026Review
- Unraveling Emerging Data on Lipoprotein(a)-Driven Cardiovascular Disease via Multiomics: A Review.Global heart · 2026Review
- Clinical significance of lipoprotein(a) as a residual risk factor for atherosclerotic coronary plaque progression in statin-treated patients with coronary artery disease.Scientific reports · 2025Observational
32 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 10 institutions in 5 countries.
Funding
Abstract
backgroundLipoprotein(a) [Lp(a)] is associated with increased risk of myocardial infarction, although the mechanism for this observation remains uncertain.
objectivesThis study aims to investigate whether Lp(a) is associated with adverse plaque progression.
methodsLp(a) was measured in patients with advanced stable coronary artery disease undergoing coronary computed tomography angiography at baseline and 12 months to assess progression of total, calcific, noncalcific, and low-attenuation plaque (necrotic core) in particular. High Lp(a) was defined as Lp(a) ≥ 70 mg/dL. The relationship of Lp(a) with plaque progression was assessed using linear regression analysis, adjusting for body mass index, segment involvement score, and ASSIGN score (a Scottish cardiovascular risk score comprised of age, sex, smoking, blood pressure, total and high-density lipoprotein [HDL]-cholesterol, diabetes, rheumatoid arthritis, and deprivation index).
resultsA total of 191 patients (65.9 ± 8.3 years of age; 152 [80%] male) were included in the analysis, with median Lp(a) values of 100 (range: 82 to 115) mg/dL and 10 (range: 5 to 24) mg/dL in the high and low Lp(a) groups, respectively. At baseline, there was no difference in coronary artery disease severity or plaque burden. Patients with high Lp(a) showed accelerated progression of low-attenuation plaque compared with low Lp(a) patients (26.2 ± 88.4 mm
conclusionsAmong patients with advanced stable coronary artery disease, Lp(a) is associated with accelerated progression of coronary low-attenuation plaque (necrotic core). This may explain the association between Lp(a) and the high residual risk of myocardial infarction, providing support for Lp(a) as a treatment target in atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.